Evidence map›Paper›PMID 40697391›Full record

ArticleOphthalmology science

Retinal Blood Flow Decreases after Treatment with Bevacizumab for Retinopathy of Prematurity.

Joyce Wang, Shaiza Mansoor, Jeong-Yoon Wu, Christina Kilby, He Forbes, Ria Kapoor, Sarah Ward, Jason Zhou, Kristin Williams, Moran Roni Levin and 5 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ophthalmology science. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07641738 (Evaluation of Patients With Retinal Disorders Utilizing the XyCAM CRE Camera.), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07641738 not yet recruitingnot on this map

Evaluation of Patients With Retinal Disorders Utilizing the XyCAM CRE Camera.

TypeobservationalSponsorStuart Terry Eye AssociatesRan2026 to 2030Enrolled350ConditionsMicrovascular Disease, Retinal DiseaseArmsXyCAM CRE Imaging
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Joyce WangSchool of Medicine, University of Maryland, Baltimore, Maryland.
Shaiza MansoorSchool of Medicine, University of Maryland, Baltimore, Maryland.
Jeong-Yoon WuDepartment of Ophthalmology and Visual Sciences, School of Medicine, University of Maryland, Baltimore, Maryland.
Christina KilbyDepartment of Ophthalmology and Visual Sciences, School of Medicine, University of Maryland, Baltimore, Maryland.
He ForbesDepartment of Ophthalmology and Visual Sciences, School of Medicine, University of Maryland, Baltimore, Maryland.
Ria KapoorDepartment of Ophthalmology and Visual Sciences, School of Medicine, University of Maryland, Baltimore, Maryland.
Sarah WardDepartment of Ophthalmology and Visual Sciences, School of Medicine, University of Maryland, Baltimore, Maryland.
Jason ZhouSchool of Medicine, University of Maryland, Baltimore, Maryland.
Kristin WilliamsDepartment of Ophthalmology and Visual Sciences, School of Medicine, University of Maryland, Baltimore, Maryland.
Moran Roni LevinDepartment of Ophthalmology and Visual Sciences, School of Medicine, University of Maryland, Baltimore, Maryland.
Sripriya SundararajanDivision of Neonatology, School of Medicine, University of Maryland, Baltimore, Maryland.
Larry MagderSchool of Public Health, University of Maryland, Baltimore, Maryland.
Avigyan SinhaVasoptic Medical, Inc., Columbia, Maryland.
Abhishek RegeVasoptic Medical, Inc., Columbia, Maryland.
Janet L AlexanderDepartment of Ophthalmology and Visual Sciences, School of Medicine, University of Maryland, Baltimore, Maryland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To compare total retinal blood flow (TRBF) rates before and after retinopathy of prematurity (ROP) treatment with intravitreal bevacizumab using laser speckle contrast imaging (LSCI). Design: A prospective cohort study. Participants: Twenty-five eyes from 14 premature infants in the neonatal intensive care unit receiving intravitreal bevacizumab for treatment-requiring ROP. Methods: Total retinal blood flow was measured using LSCI longitudinally before and after bevacizumab treatment. Subject characteristics and clinical ROP features, including the need for ROP retreatment, were included in regression analysis using generalized estimating equations to account for 2 eyes per subject and longitudinal measures over time. Main Outcome Measures: The main outcome measure was TRBF, which includes components of peak, mean, and dip over the cardiac cycle. Results: Before ROP treatment, subjects had a peak TRBF of 11.1 ± 2.9 a.u. compared to 8.6 ± 1.8 a.u. after treatment (mean difference = 2.5 a.u., Conclusions: We observed lower TRBF after treatment with intravitreal bevacizumab. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Indexed as

Anti-VEGFBevacizumabLaser speckle contrast imagingPlus diseaseRetinopathy of prematurity

Identifiers

PMID40697391
PMCPMC12281122

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.